127 related articles for article (PubMed ID: 2354227)
21. Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
Kirkpatrick B; Carpenter WT; Maeda K; Buchanan RW; Breier A; Tamminga CA
Biol Psychiatry; 1992 Dec; 32(11):1049-54. PubMed ID: 1467385
[TBL] [Abstract][Full Text] [Related]
22. Prolactin and growth hormone responses to growth hormone-releasing hormone in acute schizophrenia.
Nerozzi D; Magnani A; Sforza V; Scaramucci E; Cerilli M; Moretti C; Antonozzi I; Frajese G
Neuropsychobiology; 1990; 23(1):15-7. PubMed ID: 2280826
[TBL] [Abstract][Full Text] [Related]
23. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia.
Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS
Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048
[TBL] [Abstract][Full Text] [Related]
24. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
Santos JL; Cabranes JA; Vazquez C; Fuentenebro F; Almoguera I; Ramos JA
Biol Psychiatry; 1989 Aug; 26(4):381-8. PubMed ID: 2669981
[TBL] [Abstract][Full Text] [Related]
25. Prolactin response to submaximal stimulation by TRH in nonaffective psychoses.
Spoov J; Bredbacka PE; Appelberg B; Katila H; Karonen SL; Rimón R; Sarna S
Biol Psychiatry; 1991 Feb; 29(3):204-10. PubMed ID: 1673063
[TBL] [Abstract][Full Text] [Related]
26. Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables.
Mauri MC; Vita A; Giobbio GM; Ferrara A; Dieci M; Bitetto A; Altamura AC
Int Clin Psychopharmacol; 1994; 9(1):3-7. PubMed ID: 8195579
[TBL] [Abstract][Full Text] [Related]
27. Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study.
Zhang XY; Zhou DF; Cao LY; Zhang PY; Wu GY; Shen YC
Psychopharmacology (Berl); 2005 Feb; 178(1):35-40. PubMed ID: 15289996
[TBL] [Abstract][Full Text] [Related]
28. Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia.
Mohr P; Horácek J; Motlová L; Libiger J; Czobor P
Schizophr Res; 1998 Feb; 30(1):91-9. PubMed ID: 9542792
[TBL] [Abstract][Full Text] [Related]
29. Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility.
Santos JL; Ramos JA; Prieto P; Almoguera I; Vazquez C; Rubio ME; Cabranes JA
Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):917-25. PubMed ID: 2813809
[TBL] [Abstract][Full Text] [Related]
30. Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients.
Den Boer JA; Ravelli DP; Huisman J; Ohrvik J; Verhoeven WM; Westenberg HG
Psychopharmacology (Berl); 1990; 102(1):76-84. PubMed ID: 1975448
[TBL] [Abstract][Full Text] [Related]
31. Abnormal prolactin response to haloperidol challenge in men with schizophrenia.
Keks NA; Copolov DL; Singh BS
Am J Psychiatry; 1987 Oct; 144(10):1335-7. PubMed ID: 3661768
[TBL] [Abstract][Full Text] [Related]
32. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
[TBL] [Abstract][Full Text] [Related]
33. Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia.
Mohr P; Horácek J; Motlová L; Libiger J; Czobor P
Psychopharmacology (Berl); 1999 Jan; 141(3):322-5. PubMed ID: 10027514
[TBL] [Abstract][Full Text] [Related]
34. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
Magliozzi JR; Hollister LE; Arnold KV; Earle GM
Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
[TBL] [Abstract][Full Text] [Related]
35. The Brief Psychiatric Rating Scale (BPRS) and the Nurses' Observation Scale for Inpatient Evaluation (NOSIE) in the evaluation of positive and negative symptoms.
Dingemans PM
J Clin Psychol; 1990 Mar; 46(2):168-74. PubMed ID: 2324299
[TBL] [Abstract][Full Text] [Related]
36. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder.
Pearlson GD; Wong DF; Tune LE; Ross CA; Chase GA; Links JM; Dannals RF; Wilson AA; Ravert HT; Wagner HN
Arch Gen Psychiatry; 1995 Jun; 52(6):471-7. PubMed ID: 7771917
[TBL] [Abstract][Full Text] [Related]
37. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
Nagaoka S; Iwamoto N; Arai H
Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
[TBL] [Abstract][Full Text] [Related]
38. Prolactin responses to domperidone in chronic schizophrenia.
Nerozzi D; Magnani A; Dastoli C; Ferri E; Capesciotti G; Antonozzi I; Frajese G; Meltzer HY
Psychiatry Res; 1992 May; 42(2):159-69. PubMed ID: 1631251
[TBL] [Abstract][Full Text] [Related]
39. Quetiapine : A Review of its Use in Schizophrenia.
Gunasekara NS; Spencer CM
CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
[TBL] [Abstract][Full Text] [Related]
40. Prolactin secretion response to TRH stimulation in acute and chronic schizophrenic patients under neuroleptic treatment.
Cabranes JA; Fuentenebro F; Recio MN; Borque M; Almoguera MI
Int Pharmacopsychiatry; 1982; 17(1):1-7. PubMed ID: 6123489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
